FDA Finalizes Guidance to Broaden Cancer Trial Eligibility

The FDA has finalized guidance aimed at broadening eligibility criteria for cancer clinical trials. This regulatory action is expected to impact clinical practice by making trials more accessible to a wider range of patients, potentially accelerating research and development for new cancer treatments.